Optimizing Immunomodulators and Anti-TNF Agents in the Therapy of Crohn Disease
- 11 April 2012
- journal article
- review article
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 41 (2) , 393-409
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatmentGut, 2011
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic ReviewAmerican Journal of Gastroenterology, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Transmembrane TNF- : structure, function and interaction with anti-TNF agentsRheumatology, 2010
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical Pharmacology, 2009
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s diseaseGut, 2007
- Clinical Pharmacokinetics and Use??of??InfliximabClinical Pharmacokinetics, 2007
- Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel DiseasePharmacoEconomics, 2006